A Phase Ib Study on the Combination of Trabectedin and Olaparib in Unresectable Advanced/Metastatic Sarcomas After Failure of Standard Therapies
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 14 Mar 2017
At a glance
- Drugs Olaparib (Primary) ; Trabectedin (Primary)
- Indications Sarcoma
- Focus Adverse reactions
- Acronyms TOMAS
- 07 Mar 2017 Planned End Date changed from 1 Jun 2017 to 1 Aug 2017.
- 07 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 07 Jun 2016 Interim results (n=24) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology